1型心肾综合征相关炎性因子水平变化及临床意义被引量：1

导出

摘要目的探讨1型心肾综合征（cardiorenal syndrome,CRS）患者相关性因子水平变化及其临床意义。方法回顾性分析2013年12月—2015年12月于赣榆县人民医院心内科和徐州医学院第二附属医院心内科住院确诊的心力衰竭患者120例,依据入院后有无发生急性肾损伤分为：1型CRS组（n=60）和单纯心力衰竭组（n=60）,经过积极抗心力衰竭治疗后,比较两组治疗前后N-末端脑钠肽前体（N-terminal pro brain natriuretic peptide,NT-pro BNP）、血清糖类抗原125（carbohydrate antigen 125,CA125）、血清胱抑素C（cystatin C,Cys-C）、血尿素氮（blood urea nitrogen,BUN）、血清肌酐（serum creatinine,Scr）、射血分数（ejection fraction,EF）等的水平。计量资料比较采用t检验,计数资料比较采用χ~2检验,P〈0.05为差异有统计学意义。结果两组患者入院前BUN[（11.92±2.93）、（7.65±2.14）mmol/L]、Scr[（126.20±21.68）、（87.77±19.42）μmol/L]、EF[（37.26±10.45）、（49.34±10.26）%]比较,差异均有统计学意义（均P〈0.05）。与单纯心力衰竭组比较[（48.57±22.39）、（25.81±15.47）μ/ml与（1.30±0.26）、（1.08±0.17）],治疗前后1型CRS组血清CA125[（62.45±29.35）、（39.38±18.47）U/ml]、Cys-C水平[（1.71±0.23）、（1.42±0.19）mg/L]均较高,差异均有统计学意义（均P〈0.05）。结论 CA125、Cys-C可作为确诊1型CRS、评价疾病进展的生物标记物。

作者谢军王静李达张毅李勇

机构地区赣榆县人民医院心内科徐州医学院第二附属医院

出处《社区医学杂志》 2016年第13期37-39,共3页 Journal Of Community Medicine

关键词 1型心肾综合征 CA125 NT-pro BNP Cys-C.

分类号 R541 [医药卫生—心血管疾病] R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献13

1郭俊,冯灿,陆阳,赵仙先.心肾综合征的诊治及研究进展[J].国际心血管病杂志,2015,42(1):19-22. 被引量：12
2Royston P,Altman DG.Risk stratification for in-hospital mortality in acutely decompensated heart failure[J].JAMA,2005,293(20):2467-2468.
3Volpe M,Rubattu S,Burnett J,et al.Natriuretic peptides in cardiovascular diseases:current use and perspectives[J].Eur Heart J,2014,35(7):419-425.
4Park M,Vittinghoff E,Shlipak MG,et al.Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study[J].Am Heart J,2014,168(6):931-939.
5Ibrahim N,Januzzi JL.The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis,prognosis and management[J].Expert Rev Cardiovasc Ther,2015,13(9):1017-1030.
6Huang F,Zhang K,Chen J,et al.Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion[J].Clin Biochem,2013,46(16):1694-1700.
7Yilmaz H,Gürel OM,Celik HT,et al.CA 125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis[J].Ren Fail,2014,36(2):210-216.
8Ye X,Wei L,Pei X,et al.Application of creatinine-and/or cystatin C-based glomerular filtration rate estimation equations in elderly Chinese[J].Clin Interv Aging,2014,9(4):1539-1549.
9Charlton JR,Portilla D,Okusa MD.A basic science view of acute kidney injury biomarkers[J].Nephrol Dial Transplant,2014,29(7):1301-1311.
10Vizzardi E,D’Aloia A,Pezzali N,et al.Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients[J].J Card Fail,2012,18(1):68-73.

二级参考文献27

1Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative [J]. Eur Heart J, 2010, 31 (6) :703-711.
2Haase M, Mtiller C, Damman K, et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI) for the Acute Dialysis Quality Initiative (ADQI) [J]. Contrib Nephrol, 2013, 182:99-116.
3Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome[J]. J Am Coil Cardiol, 2008, 52(19):1527-1539.
4Chan EJ, Dellsperger NC. Update on cardiorenal syndrome: a clinical conundrum [J]. Adv Petit Dial, 2011, 27:82-86.
5Cruz DN, Sehmidt-Ott KM, Veseovo G, et al. Pathophy- siology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI) [J]. Contrib Nephrol, 2013, 182:117-136.
6Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis[J]. JAMA , 2005,293(5) :572-580.
7Thomas Mueller , Benjamin , Dieplinger, et al. The Presage ST2 Assay: analytical considerations and clinical applications fora high-sensitivity assay for measurement of soluble ST2 [J]. Expert Rev Mol Diagn, 2003, 13(1) :13-30.
8Cruz DN, Goh CY, Haase-Fielitz A, et al. Early biomarkers of renal injury[J]. Congest Heart Fail, 2010, 16(Suppl 1): S25-S31.
9Zhu J, Yin R, Wu H, et al. Cystatin C as a reliable marker of renal function following heart valve replacement surgery with cardio-pulmonary bypass [J]. Clin Chim Acta, 2006, 374(1-2) : 116-121.
10Hawkins R. New biomarkers of acute kidney injury and the eardio-renal syndrome [J]. Korean J LabMed, 2011, 31 (2) : 72- 80.